Bristol Myers Squibb has a generally strong reputation as one of largest and most respected pharmaceutical companies in world, with long history and significant contributions to medicine, though like all large pharma companies it has faced controversies. Bristol Myers Squibb, commonly called BMS, headquartered in Princeton, New Jersey, formed by merger of Bristol-Myers and Squibb in 1989, is known for strong reputation in oncology, immunology, and cardiovascular research, producing blockbuster drugs like Eliquis for blood clots, Opdivo and Yervoy for cancer immunotherapy, and Revlimid for multiple myeloma after acquiring Celgene in 2019 for 74 billion dollars. BMS is considered leader in immuno-oncology and has strong R and D pipeline, with reputation for innovation and scientific rigor, ranked among top pharma companies by revenue over 40 billion dollars. It is also known for corporate responsibility, sustainability initiatives, and employee benefits, often appearing on Fortune Most Admired Companies list. However, like other pharma companies, it has faced criticism for high drug prices, patent litigation to extend exclusivity, and occasional lawsuits related to drug side effects and marketing practices. Overall reputation among healthcare professionals is positive for quality and efficacy of medicines, among investors is solid for dividend and growth, and among patients is mixed due to pricing concerns common to industry.
1 votes
Marked as accepted